Abstract
JUPITER has demonstrated that combining hsCRP testing with traditional testing of lipids can reduce incident CVD in high-risk asymptomatic individuals by 44% and all-cause mortality by approximately 20%, extending the therapeutic use of statins for the primary prevention of CVD. Guidelines for practitioners could include testing asymptomatic individuals for increased concentrations of hsCRP in men ≥50 years and women ≥60 years when LDL-C concentrations are not increased and for whom the decision to treat with statin therapy is not otherwise clear.
Original language | English (US) |
---|---|
Pages (from-to) | 219-228 |
Number of pages | 10 |
Journal | Clinical chemistry |
Volume | 55 |
Issue number | 2 |
DOIs | |
State | Published - Feb 1 2009 |
ASJC Scopus subject areas
- Clinical Biochemistry
- Biochemistry, medical